IO101 / IO Biotech - LARVOL DELTA

IO 101—How Do They Work? (STS 2025) - No abstract available

NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation (AACR 2024) - P1/2 | "BACKGROUND: NGM707-IO-101 (NCT04913337) is a Phase 1/2, dose escalation/expansion study evaluating NGM707, a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors, as monotherapy or in combination with pembrolizumab. NGM707 in combination with pembrolizumab appears to be safe and well tolerated at all dose levels. In this advanced and metastatic solid tumor cohort, early efficacy signals have been observed. Preliminary evidence of myeloid cell reprogramming was observed in paired tumor biopsies."

Combination therapy • IO biomarker • Metastases • Oncology • Solid Tumor

Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors (AACR 2024) - P1/2 | "NGM707-IO-101 (NCT04913337) is a first-in-human Phase 1/2 clinical trial of NGM707 monotherapy and combination with pembrolizumab. Baseline gene expression signatures have shown an encouraging association with clinical benefit from NGM707 and merit further investigation as promising predictive biomarkers. Protein and gene expression changes reflecting the expected modes of action of NGM707 and pembrolizumab were observed in both peripheral blood and tumor biopsies following treatment."

Biomarker • Clinical • Metastases • P1 data • PK/PD data • Oncology • Solid Tumor • CD163 • CD4 • CD8 • CXCL9 • LILRB1

A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC (IASLC-WCLC 2019) - P1/2; "...Our first-generation IDO vaccine (IO101) has shown promising antitumor activity and a favorable safety in heavily pretreated NSCLC patients (Iversen, CCR 2013)...Cohort A: IO102 (100µg s.c.) and pembrolizumab (200 mg) (PD-L1 ≥ 50%); Cohort B: IO102, pembrolizumab and carboplatin plus pemetrexed (PD-L1 < 50%)... Section not applicable"

Clinical • IO biomarker • P1/2 data • PD(L)-1 Biomarker • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer (ELCC 2019) - P1/2; "...Our first-generation IDO vaccine (IO101) has shown promising antitumor activity and a favorable safety in heavily pretreated NSCLC patients (Iversen, CCR 2013)...Cohort A: IO102 (100µg s.c.) and pembrolizumab (200 mg) (PD-L1 ≥ 50%); Cohort B: IO102, pembrolizumab and carboplatin plus pemetrexed (PD-L1 < 50%)...Secondary endpoints include ORR per iRECIST, duration of response, progression free survival, overall survival, and biomarkers including immunoscore in tissue, tumour mutational burden and immunomonitoring in blood. The study is enrolling in Europe and US: EudraCT Number 2018-000139-28 / IND Number 018081."

Clinical • IO biomarker • P1/2 data • PD(L)-1 Biomarker • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

First-in-human Study of NGM707, An ILT2/ILT4 Dual Antagonist Antibody in Advanced or Metastatic Solid Tumors: Preliminary Monotherapy Dose Escalation Data (ESMO-IO 2022) - P1/2 | "Methods NGM707-IO-101 is a phase 1/2, dose escalation/expansion study evaluating NGM707 as a monotherapy and in combination with pembrolizumab. Preliminary evidence of myeloid reprogramming was seen in tumor biopsies. Monotherapy tx is ongoing and enrollment of pembrolizumab combination cohorts has been initiated."

Monotherapy • P1 data • Oncology • Solid Tumor • CD163

Bis-(3-methyl-1-propyl-1,3-di-hydro-1H-imidazol-2-yl-idene)silver(I) chlor-ido(5,10,15,20-tetra-phenyl-porphin-ato)cadmate(II). (PubMed, IUCrdata) - "The structure of the title salt, [Ag(CHN)][CdCl(CHN)], at 150 K has triclinic symmetry. One of the phenyl rings bonded to the porphyrin mol-ecule and the propyl groups of both yl-idene mol-ecules coordinating to silver are disordered over two positions."

Journal

An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer (ELCC 2019) - P1/2; "...Our first-generation IDO vaccine (IO101) has shown promising antitumor activity and a favorable safety in heavily pretreated NSCLC patients (Iversen, CCR 2013)...Cohort A: IO102 (100µg s.c.) and pembrolizumab (200 mg) (PD-L1 ≥ 50%); Cohort B: IO102, pembrolizumab and carboplatin plus pemetrexed (PD-L1 < 50%)...Secondary endpoints include ORR per iRECIST, duration of response, progression free survival, overall survival, and biomarkers including immunoscore in tissue, tumour mutational burden and immunomonitoring in blood. The study is enrolling in Europe and US: EudraCT Number 2018-000139-28 / IND Number 018081."

Clinical • IO Biomarker • P1/2 data • PD(L)-1 Biomarker • Tumor Mutational Burden

Induced pluripotent stem cell line heterozygous for p.R501X mutation in filaggrin: KCLi003-A. (PubMed, Stem Cell Res) - "We have generated an induced pluripotent stem cell (iPSC) line KCLi003-A (iOP101) from epidermal keratinocytes of a female donor, heterozygous for the loss-of-function mutation p.R501X in the filaggrin gene (FLG), using non-integrating Sendai virus vectors. Derivation and expansion of iPSCs were performed under xeno-free culture conditions. Characterization and validation of KCLi003-A line included molecular karyotyping, mutation screening using restriction enzyme digestion, next generation sequencing (NGS), while pluripotency and differentiation potential were confirmed by expression of associated markers in vitro and by in vivo teratoma assay."

Journal • Oncology

Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report. (PubMed, Front Immunol) - P1; " Fifteen HLA-A2-positive patients with stable stage III-IV NSCLC after standard chemotherapy were treated with subcutaneous vaccinations (100 μg IDO5 peptide, sequence ALLEIASCL, formulated in 900 μl Montanide) biweekly for 2.5 months and thereafter monthly until progression or up to 5 years... IDO peptide vaccination was well tolerated for administration up to 5years. Two of 15 patients are long-term responders with ongoing clinical response 6 years after 1st vaccination."

Clinical • Journal • P1 data